Park Ha Biological Technology (BYAH) Q4 2024 earnings summary

Executive summary

• Operates as a holding company with primary business in skincare product development, direct sales, and franchise alliances in China, with 45 franchisees as of October 31, 2024.

• Completed an IPO in December 2024, listing on Nasdaq under the symbol PHH, raising $4.8 million gross proceeds.

• Revenue streams include product sales (to franchisees and non-franchisees) and franchise fees, with a focus on expanding brand presence and franchise network.

Financial highlights

• FY2024 revenue: $2.38M, down 3% from $2.46M in FY2023, mainly due to a decrease in franchise fees.

• Net income for FY2024: $478.6K, a 44% decrease from $852K in FY2023, attributed to higher general/admin expenses and lower franchise fee revenue.

• Gross profit margin improved to 92% in FY2024 from 87% in FY2023, driven by product mix optimization and cost savings.

• Cash and cash equivalents as of October 31, 2024: $547.5K, down from $1.03M in 2023.

• Allowance for expected credit losses increased to $179.9K in FY2024 from $152.1K in FY2023, reflecting higher accounts receivable and delayed payments from franchisees.

Outlook and guidance

• Management expects continued growth through franchise expansion, R&D investment, and digital marketing.

• Plans to strengthen product development, expand training, and improve supply chain capacity.

• No specific quantitative forward guidance provided.